COVID-19 Group Testing Method Delivers Results 13 Times Faster than Individual Testing of Each Sample
|
By LabMedica International staff writers Posted on 30 Mar 2021 |

Illustration
A new group method of testing for COVID-19 allows results to be obtained 13 times faster as compared to individual testing of each sample.
The new method developed by researchers from the HSE Laboratory of Algorithms and Technologies for Networks Analysis (Nizhny Novgorod, Russia) and Vilnius University (Vilnius, Lithuania) can be used for asymptomatic populations with seemingly low incidence of coronavirus cases, where it will help detect the infected individuals at a maximum speed with a minimum number of tests, and timely apply the quarantine measures in order to prevent spreading of the disease.
Present COVID-19 testing solutions are based on the extraction of RNA from patients using oropharyngeal and nasopharyngeal swabs, and then testing with real-time PCR for the presence of specific RNA filaments identifying the virus. The speed of this approach is limited by the availability of reactants, trained technicians and laboratories. One way to speed up the testing procedures is group testing, where the swabs of multiple patients are grouped together and tested. The swabs from groups that return a positive result are then tested individually in order to detect specific COVID-19 positive patients. This approach helps decrease the number of tests twofold or more (depending on the spread of the disease) as compared to individual testing of each swab.
For example, suppose 96 samples should be tested and pools of up to 12 samples are possible. In individual testing, 96 tests are necessary. In pool testing, 8 pools of 12 samples are taken and testing is performed. If the result of one pool is positive, then additional 12 individual tests are needed. If two or three groups return a positive result, 24 or 36 additional tests are required, which, together with the first eight tests, will mean a decrease in the number of tests from two to five times as compared to individual testing. The researchers believe that the number of tests can be decreased by optimizing the size of groups that takes into account the total number of swabs and the forecasted number of infected individuals. As the number of infected individuals increases, the possibility of saving swabs decreases but is still about 40% in the event of an incidence of 100 positive samples per 1,000, and 18% for an incidence of 200 per 1,000.
There are ways to optimize group testing, such as choosing the optimal group size based on the total number of swabs and the projected level of disease spreading. Another is the binary splitting method, in which a positive group is split into halves and is tested again, until individual positive swabs are detected. The second method, however, is very time-consuming, which decreases its attractiveness during a pandemic. In addition, to optimize group testing, transposition-based replication is used: after grouping the swabs, researchers form additional control groups from the same swabs and test them together with the main groups. This helps further cut the number of tests, and if the disease levels are low, it also helps to detect positive swabs in one step, which speeds up the testing considerably.
However, this method does not allow for experimenting with group sizes to detect the optimal group size under specific conditions. Researchers from HSE University and Vilnius University suggested OptReplica technology, which uses a more complicated algorithm of swab grouping in key and control groups and helps decrease the number of control groups. In addition, the algorithm helps calculate the optimal group size for the present number of swabs and the forecasted level of disease spreading. The researchers conducted experimental research on samples of 96 and 384 swabs, carrying out 100 randomized tests for each sample size, and compared the effectiveness of transposition-based replication and OptReplica method for different levels of disease incidence. The studies have shown that if the optimal size of groups is chosen, OptReplica is more effective than transposition-based replication. In cases with low incidence, the use of OptReplica, a 13x average reduction of tests can be achieved compared to individual testing without time delay.
“Our simulations are actually proving that using this optimization replication strategy is always advantageous and, even in case of high spread of the disease (10% or 20% of positives in the population), we are still competitive with individual testing strategy,” explained Mario Guarracino, Chief Research Fellow of the Laboratory of Algorithms and Technologies for Networks Analysis.
Related Links:
HSE Laboratory of Algorithms and Technologies for Networks Analysis
Vilnius University
The new method developed by researchers from the HSE Laboratory of Algorithms and Technologies for Networks Analysis (Nizhny Novgorod, Russia) and Vilnius University (Vilnius, Lithuania) can be used for asymptomatic populations with seemingly low incidence of coronavirus cases, where it will help detect the infected individuals at a maximum speed with a minimum number of tests, and timely apply the quarantine measures in order to prevent spreading of the disease.
Present COVID-19 testing solutions are based on the extraction of RNA from patients using oropharyngeal and nasopharyngeal swabs, and then testing with real-time PCR for the presence of specific RNA filaments identifying the virus. The speed of this approach is limited by the availability of reactants, trained technicians and laboratories. One way to speed up the testing procedures is group testing, where the swabs of multiple patients are grouped together and tested. The swabs from groups that return a positive result are then tested individually in order to detect specific COVID-19 positive patients. This approach helps decrease the number of tests twofold or more (depending on the spread of the disease) as compared to individual testing of each swab.
For example, suppose 96 samples should be tested and pools of up to 12 samples are possible. In individual testing, 96 tests are necessary. In pool testing, 8 pools of 12 samples are taken and testing is performed. If the result of one pool is positive, then additional 12 individual tests are needed. If two or three groups return a positive result, 24 or 36 additional tests are required, which, together with the first eight tests, will mean a decrease in the number of tests from two to five times as compared to individual testing. The researchers believe that the number of tests can be decreased by optimizing the size of groups that takes into account the total number of swabs and the forecasted number of infected individuals. As the number of infected individuals increases, the possibility of saving swabs decreases but is still about 40% in the event of an incidence of 100 positive samples per 1,000, and 18% for an incidence of 200 per 1,000.
There are ways to optimize group testing, such as choosing the optimal group size based on the total number of swabs and the projected level of disease spreading. Another is the binary splitting method, in which a positive group is split into halves and is tested again, until individual positive swabs are detected. The second method, however, is very time-consuming, which decreases its attractiveness during a pandemic. In addition, to optimize group testing, transposition-based replication is used: after grouping the swabs, researchers form additional control groups from the same swabs and test them together with the main groups. This helps further cut the number of tests, and if the disease levels are low, it also helps to detect positive swabs in one step, which speeds up the testing considerably.
However, this method does not allow for experimenting with group sizes to detect the optimal group size under specific conditions. Researchers from HSE University and Vilnius University suggested OptReplica technology, which uses a more complicated algorithm of swab grouping in key and control groups and helps decrease the number of control groups. In addition, the algorithm helps calculate the optimal group size for the present number of swabs and the forecasted level of disease spreading. The researchers conducted experimental research on samples of 96 and 384 swabs, carrying out 100 randomized tests for each sample size, and compared the effectiveness of transposition-based replication and OptReplica method for different levels of disease incidence. The studies have shown that if the optimal size of groups is chosen, OptReplica is more effective than transposition-based replication. In cases with low incidence, the use of OptReplica, a 13x average reduction of tests can be achieved compared to individual testing without time delay.
“Our simulations are actually proving that using this optimization replication strategy is always advantageous and, even in case of high spread of the disease (10% or 20% of positives in the population), we are still competitive with individual testing strategy,” explained Mario Guarracino, Chief Research Fellow of the Laboratory of Algorithms and Technologies for Networks Analysis.
Related Links:
HSE Laboratory of Algorithms and Technologies for Networks Analysis
Vilnius University
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Blood and Spinal Fluid Biomarker May Help Track Early Huntington’s Disease
Huntington’s disease is a genetic disorder caused by a mutation in the HTT gene that progressively affects movement, cognition, behavior, and independence. Although mutation carriers can be identified... Read more
New Biomarker Offers Longer Detection Window for Suspected GHB Exposure
Gamma-hydroxybutyrate (GHB) can be used recreationally or administered covertly to incapacitate victims. Forensic confirmation is challenging because the substance is rapidly eliminated, with typical detection... Read moreMolecular Diagnostics
view channelCombined Blood Tests Help Clarify Colorectal Cancer Recurrence Risk
Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related mortality. For patients undergoing curative-intent surgery for metastatic disease, predicting... Read more
Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer
Advanced prostate cancer can progress despite hormone-based treatment, with imaging sometimes revealing only limited areas of active disease. For men with hormone-resistant oligoprogressive prostate cancer,... Read moreHematology
view channel
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read more
New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients
Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more
Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers
Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more








